Welcome to our dedicated page for Eton Pharmaceuticals SEC filings (Ticker: ETON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eton Pharmaceuticals, Inc. (NASDAQ: ETON) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Eton’s Form 8-K filings in 2025 cover topics such as quarterly financial results, changes in independent registered public accounting firms, index inclusion, product acquisitions, and key regulatory milestones for its rare disease portfolio.
For example, a November 6, 2025 Form 8-K furnishes a press release announcing financial results for the quarter ended September 30, 2025 and explains the company’s use of non-GAAP measures like Adjusted EBITDA. Other 8-K filings describe the FDA’s acceptance of the New Drug Application for ET-600, a proprietary desmopressin oral solution, and Eton’s addition to the Russell 2000 and Russell 3000 indexes. An 8-K/A filed on November 18, 2025 provides historical financial statements and unaudited pro forma condensed combined financial information related to the acquisition of INCRELEX.
Through these filings, investors can review Eton’s reported net revenues, product sales trends, research and development spending on programs such as ET-600, ET-700, and ET-800, and general and administrative expenses associated with commercial launches. Filings also document governance and audit matters, including the June 20, 2025 8-K reporting the dismissal of Crowe LLP and the appointment of Grant Thornton LLP as the new independent auditor.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that highlight the main points of complex documents, such as 10-K annual reports, 10-Q quarterly reports, and 8-K current reports. Users can quickly understand what each filing means for Eton’s rare disease strategy, financial position, and regulatory progress, and can also monitor insider and other ownership-related filings like Forms 3, 4, and 5 when available.
Eton Pharmaceuticals chief business officer David Krempa reported new equity awards and related tax withholding transactions. On January 12, 2026, he was granted 40,655 employee stock options with an exercise price of $15.47 per share, vesting in 48 equal monthly installments until fully vested and exercisable on January 12, 2030, and expiring on January 11, 2036. He also received 25,856 restricted stock units, each representing a right to one share of Eton common stock, vesting in four equal annual installments beginning January 12, 2027, contingent on continued employment. On January 14, 2026, 1,942 shares of common stock were withheld at $15.62 per share to cover taxes on RSU vesting, leaving 630,238 common shares beneficially owned directly, 670,893 derivative securities from options, and 696,749 derivative securities including RSUs.
Eton Pharmaceuticals Chief Financial Officer James R. Gruber reported routine equity compensation activity and related tax withholding. On January 12, 2026, he received an option grant for 40,655 shares of common stock at an exercise price of $15.47 per share, scheduled to vest in 48 equal monthly installments until January 12, 2030. He also received 25,856 restricted stock units, each representing one share of common stock, which vest in four equal annual installments beginning January 12, 2027, contingent on continued employment.
On January 14, 2026, 2,293 shares of common stock were withheld and sold at a weighted average price of $15.47 to satisfy withholding taxes upon vesting of restricted stock units. After this transaction, Gruber beneficially owned 213,420 shares of common stock directly.
Form 144 discloses a planned sale of restricted or control securities. The filer intends to sell 1,942 shares of common stock through Raymond James & Associates on the NASDAQ, with an aggregate market value of $30,334.04. The filing notes that 26,820,000 shares of this class were outstanding.
The securities to be sold were acquired as a grant from the issuer on 01/13/2026, with a stated amount of 6,469 shares and a cash payment date of 01/14/2026. The notice also reports that David Krempa sold 6,264 common shares on 12/12/2025 for gross proceeds of $106,460.00. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer.
Eton Pharmaceuticals insider plans a modest stock sale under Rule 144. A notice was filed to sell 2,293 shares of common stock through Raymond James & Associates, with an aggregate market value of $35,483.96, on or about 01/14/2026 on the NASDAQ. The filing notes that 26,820,000 shares of the issuer’s common stock were outstanding.
The securities to be sold are part of 6,469 common shares acquired on 01/13/2026 via a grant from the issuer, with cash noted as the form of payment dated 01/14/2026. Over the prior three months, James R. Gruber sold 4,524 common shares on 12/12/2025 for gross proceeds of $76,883.00. The signer represents that they are not aware of any undisclosed material adverse information about the issuer.
An insider of the issuer, Sean Brynjelsen, has filed a notice to sell 5,015 shares of common stock through Raymond James & Associates on or about January 14, 2026, with trading on NASDAQ. The aggregate market value of the planned sale is listed as $77,182.35, while the issuer had 26,820,000 shares of common stock outstanding. The filing also shows that Brynjelsen previously sold 6,732 common shares on December 12, 2025 for $113,316.00. The securities to be sold relate to a grant of 180,001 common shares acquired from the issuer on January 13, 2026, with cash payment dated January 14, 2026.
Eton Pharmaceuticals’ Chief Commercial Officer James R. Gruber reported a small equity-compensation-related stock disposition.
On December 12, 2025, 85 shares of Eton common stock were withheld by the issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units, with shares sold in multiple trades at prices ranging from $16.90 to $16.91 and a weighted average sales price reported. After this transaction, Gruber beneficially owned 2,403 Eton Pharmaceuticals common shares directly.
Eton Pharmaceuticals’ Chief Business Officer reported routine equity compensation and related share withholding. On 12/11/2025, the officer was awarded 5,300 restricted stock units (RSUs), each representing a contingent right to receive one share of Eton common stock, and the RSUs vest immediately as of the award date.
On 12/12/2025, 6,264 shares of common stock were disposed of under transaction code F, with a reported price of $17, in connection with shares withheld by the issuer to satisfy withholding taxes upon RSU vesting. These shares were sold in multiple trades at prices ranging from $16.83 to $17.11, and the reported price reflects the weighted average sales price. After these transactions, the officer directly beneficially owns 632,180 shares of common stock and 638,468 RSUs.
Eton Pharmaceuticals Chief Financial Officer James R. Gruber reported changes in his equity holdings. On 12/11/2025, he received 5,502 restricted stock units, each representing one share of common stock, which vested immediately and increased his total restricted stock unit holdings to 210,255. On 12/12/2025, 4,542 common shares were disposed of in a transaction coded “F” at a weighted average price of $16.99 per share, with shares withheld to satisfy tax obligations and sold in multiple trades between $16.94 and $17.07. After these transactions, he directly owned 215,713 shares of Eton common stock.
Eton Pharmaceuticals, Inc. reported an insider stock transaction by a person who serves as its President & CEO, director, and 10% owner. On 12/12/2025, 6,732 shares of common stock were disposed of in a transaction coded "F," which reflects shares withheld by the company to cover withholding taxes upon the vesting of restricted stock units. The shares were sold at a weighted average price of $16.83.
Following this tax-related transaction, the reporting person directly beneficially owns 2,894,281 shares of Eton Pharmaceuticals common stock.
Eton Pharmaceuticals filed a Form S-8 to register 1,068,363 additional shares of common stock under its 2018 Equity Incentive Plan and 150,000 additional shares under its 2018 Employee Stock Purchase Plan. These shares expand the pool available for employee equity awards and stock purchases, supporting compensation and retention programs. The company notes it previously registered 7,699,634 shares under the 2018 Equity Incentive Plan and 1,050,000 shares under the 2018 ESPP on earlier Form S-8 filings, and incorporates its latest Annual Report, Quarterly Reports, and specified Current Reports by reference.